Lung Cancer | Specialty

Savolitinib/Osimertinib Yields Responses in EGFR-Mutant, MET-Amplified, Osimertinib-Resistant NSCLC

April 10th 2024

Responses with savolitinib plus osimertinib were higher in patients with NSCLC who had higher MET amplification cutoffs vs the overall population.

Dr Jänne on an Exploratory Analysis from FLAURA2 of Baseline ctDNA in EGFR+ NSCLC

April 10th 2024

FDA Grants Fast Track Designation to PT217 for Extensive Stage Small Cell Lung Cancer

April 9th 2024

The FDA has granted fast track designation to PT217 for patients with extensive stage small cell lung cancer with disease progression.

Datopotamab Deruxtecan (Dato-DXd) in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) – Nonsquamous (NSQ) Histology in the Phase 3 TROPION-Lung01 Trial

April 9th 2024

Jacob Sands, MD, shares updated data from the phase 3 TROPION-Lung01 trial of datopotamab deruxtecan versus docetaxel in non-squamous non-small cell lung cancer recently presented at the 2024 European Lung Cancer Congress (ELCC).

FDA Grants Breakthrough Therapy Designation to First-Line Sunvozertinib for EGFR Exon 20+ NSCLC

April 8th 2024

The FDA has granted breakthrough therapy designation to sunvozertinib for patients with locally advanced or metastatic NSCLC with an EGFR exon 20 insertion mutation.

Dr Chudgar on Defining Resectability in NSCLC

April 6th 2024

Neel P. Chudgar, MD, discusses his presentation on resectability in non–small cell lung cancer at the 21st Annual Winter Lung Cancer Conference®.

Dr Schneider on Treatment Considerations After Osimertinib in EGFR+ NSCLC

April 5th 2024

Jaime Schneider, MD, PhD, discusses considerations for patients with EGFR-mutant non–small cell lung cancer that progresses on osimertinib.

Consolidation Durvalumab Generates Survival Benefit in LS-SCLC

April 5th 2024

Durvalumab monotherapy showed clinical benefit in limited-stage small cell lung cancer, according to data from the phase 3 ADRIATIC trial.

Tomivosertib Development in Frontline NSCLC Ending After Findings from KICKSTART Trial

April 4th 2024

Data from the phase 2 KICKSTART trial of tomivosertib plus pembrolizumab do not support the combination's use in patients with non–small cell lung cancer.

Dr Creelan on the Promise of Cemiplimab in Squamous NSCLC

April 3rd 2024

Ben Creelan, MD, discusses survival outcomes with cemiplimab in patients with squamous non–small cell lung cancer.

Segmenting the Utility of ADCs in NSCLC: How These Agents Are Affecting Second-Line Standards

April 3rd 2024

Keeping investigators on the edge of their seats, new data from clinical trials evaluating ADCs continue to impress.

Dr Chudgar on Resection Eligibility in NSCLC

April 1st 2024

Neel P. Chudgar, MD, discusses considerations for determining lung cancer resection eligibility and how neoadjuvant therapy may affect resectability.

Dr Paik on the Full FDA Approval of Tepotinib for mNSCLC Harboring MET Exon 14 Skipping Alterations

March 30th 2024

Paul K. Paik, MD, discusses the FDA approval of tepotinib for metastatic non–small cell lung cancer harboring MET exon 14 skipping alterations.

Dr Sabari on the FDA Approval of Frontline Amivantamab Plus Chemo in EGFR Exon 20 Insertion+ NSCLC

March 29th 2024

Joshua K. Sabari, MD, discusses the FDA approval of frontline amivantamab plus chemotherapy for NSCLC harboring EGFR exon 20 insertion mutations.

Adagrasib Improves PFS, ORR in Previously Treated KRAS G12C–Mutant NSCLC

March 28th 2024

Adagrasib improved progression-free survival and objective response rates vs docetaxel in pretreated KRAS G12C–mutant non–small cell lung cancer.

Dr Singh on Treating Lung Cancer CNS Metastasis Management Strategies

March 28th 2024

Raj Singh, MD, discusses treating patients with lung cancer with CNS metastases.

China’s NMPA Accepts sNDA for Savolitinib in Locally Advanced/Metastatic MET Exon 14+ NSCLC

March 28th 2024

China’s NMPA has accepted an sNDA for approval of savolitinib for treatment-naive locally advanced/metastatic NSCLC with MET exon 14 skipping alterations.

Perioperative Pembrolizumab Wins Approval in Europe for Resectable NSCLC at High Risk of Recurrence

March 28th 2024

The European Commission has approved neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab, for high-risk, resectable NSCLC.

TTFields Meets Time to Intracranial Progression End Point in NSCLC Brain Metastases

March 27th 2024

TTFields plus supportive care improved time to intracranial progression in patients with brain metastases from non–small cell lung cancer.

First-Line Osimertinib Plus Chemo Demonstrates Consistent Benefit in EGFR-Mutant NSCLC

March 26th 2024

Osimertinib plus chemotherapy confers superior post-progression survival outcomes vs osimertinib alone in patients with EGFR-mutated NSCLC.